Drug Trial Radar · NCT04855136
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
Jun 1, 2021
Primary completion
Apr 25, 2025
Study completion Apr 25, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be * Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) * Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.
Conditions
- Multiple Myeloma
Interventions
BB2121Biological
CAR T Cell Therapy
CC-220Drug
Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
BMS-986405Drug
gamma secretase inhibitor (GSI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Does Limiting Toxicity (DLT) rates _Phase 1Time frame: Up to 28 days from start of the combination therapy
- Complete Response Rate (CRR)_ Phase 2Time frame: Up to 24 months
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 117
Birmingham, Alabama
Local Institution - 113
San Francisco, California
Local Institution - 101
Jacksonville, Florida
Local Institution - 104
Atlanta, Georgia
Local Institution - 120
Atlanta, Georgia
Local Institution - 114
Chicago, Illinois
Local Institution - 108
Boston, Massachusetts
Local Institution - 124
Boston, Massachusetts
Local Institution - 109
Hackensack, New Jersey
New York University Langone
New York, New York
Local Institution - 110
New York, New York
Local Institution - 111
Charlotte, North Carolina
Local Institution - 118
Philadelphia, Pennsylvania
Local Institution - 103
Nashville, Tennessee
Local Institution - 107
Houston, Texas
Local Institution - 201
Pamplona, Spain
Local Institution - 202
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.